RxDoctor Payments Data

Gary Nudell, MD

Internal Medicine · West Hills, CANPI 1881617736

Payments from drug & device makers

$3,577in general payments, 2019–2025

Across 163 payments — averaging $21.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$726
  • AbbVie$535
  • AstraZeneca$285
  • Lilly USA, LLC$279
  • Pfizer$236
  • Merck$190
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$3,562100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,577 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$115,625
Medicare patients
199
Services billed
1,105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban34$36,612
OzempicSemaglutide20$34,458
JardianceEmpagliflozin19$29,184
FioricetButalb/Acetaminophen/Caffeine18$18,917
FarxigaDapagliflozin Propanediol21$16,854
SynthroidLevothyroxine Sodium39$2,559
Rosuvastatin Calcium192$2,545
Escitalopram Oxalate87$1,672
Atorvastatin Calcium168$1,507
Levothyroxine Sodium182$1,357
PaxlovidNirmatrelvir/Ritonavir14$1,318
Amlodipine Besylate104$1,242
Gabapentin47$1,209
Zolpidem Tartrate126$1,072
Valsartan41$1,064

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$236$37,93048 claims
Novo NordiskOzempic$130$34,45820 claims
Boehringer IngelheimJardiance$100$29,18419 claims
AstraZenecaFarxiga$285$16,85421 claims
AbbVieSynthroid$535$2,55939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in West Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →